Braxia Scientific is a pioneering company in the field of mental health, specializing in ketamine treatment for depression and suicidality. The company operates in the healthcare sector, focusing on advanced mental health treatments through the use of ketamine therapy. Braxia serves adults suffering from depression, suicidality, and related disorders, providing them with safe and effective treatment options administered under trained medical supervision.

The company is also a leader in psychedelic research and therapist training, having conducted the first multi-dose psilocybin trial in Canada. Braxia's business model revolves around offering clinical care through ketamine therapy, supported by digital solutions that facilitate access to treatment and improve patient outcomes. The company generates revenue by providing these specialized treatments and leveraging its expertise in psychedelic medicine.

Braxia's leadership team is actively involved in the industry, with its CEO and CMO frequently invited to speak at international conferences. The company is committed to best practices, including tracking key vitals before, during, and after psychedelic-assisted therapies to build objective data around the patient experience. This data empowers patients in their wellness journey and provides clinicians with valuable insights to enhance treatment outcomes.

Keywords: ketamine therapy, depression treatment, suicidality, mental health, psychedelic research, clinical care, digital solutions, therapist training, patient outcomes, healthcare sector.